Drug Type Aptamers |
Synonyms NOX-H94 |
Target |
Mechanism Hepc inhibitors(Hepcidin inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Kidney Failure, Chronic | Phase 2 | DE | 01 May 2014 | |
Kidney Failure, Chronic | Phase 2 | IT | 01 May 2014 | |
Kidney Failure, Chronic | Phase 2 | GB | 01 May 2014 | |
Anemia | Phase 2 | AT | 01 Sep 2012 | |
Anemia | Phase 2 | BG | 01 Sep 2012 | |
Anemia | Phase 2 | RO | 01 Sep 2012 | |
Neoplasms | Phase 2 | AT | 01 Sep 2012 | |
Neoplasms | Phase 2 | BG | 01 Sep 2012 | |
Neoplasms | Phase 2 | RO | 01 Sep 2012 | |
Endotoxemia | Phase 1 | NL | 01 Jan 2012 |
Phase 1 | 64 | ztljhnupso(eytjplqhmr) = Treatment with lexaptepid was generally safe and well tolerated, with mild and transient transaminase increases at doses ≥2.4 mg·kg(-1) and with local injection site reactions after s.c. but not after i.v. administration. bsjmklmhxb (gotzczenwn ) | Positive | 01 May 2016 | |||
Placebo | |||||||
Phase 1 | 24 | psautzwmmd(azxzzsipvi) = swzkrrvxdo awunfxnswk (atpmudysbw ) | - | 23 Oct 2014 | |||
Phase 2 | 12 | aggzunnbic(tarbgizcyn) = erguitpkpg mznwrxjlue (cetxtqevcu ) View more | Positive | 01 Oct 2014 |